Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Viktrup

Showing results (51-60 of 111) with videos related to

Pageof 12
Sort By:
Maturitas|June 13, 2008
Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinenceJules H Schagen van Leeuwen, Rainer R Lange, Aino Fianu Jonasson, et al.
Current Medical Research and Opinion|November 26, 2009
Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinenceLinda Cardozo, Rainer Lange, Simon Voss, et al.
Neurology and Therapy|April 10, 2025
Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records StudyOralee J Varnado, Michelle Vu, Gilwan Kim, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 11, 2012
Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian menOsamu Yokoyama, Masaki Yoshida, Sae Chul Kim, et al.
Urology|February 19, 2010
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunctionGregory A Broderick, Gerald B Brock, Claus G Roehrborn, et al.
Headache|April 22, 2026
Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH studyShivang Joshi, Cristina Tassorelli, Manjit Matharu, et al.
European Urology|May 5, 2009
Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasiaHartmut Porst, Kevin T McVary, Francesco Montorsi, et al.
BJU International|September 8, 2009
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatmentClaus G Roehrborn, Jed C Kaminetsky, Stephen M Auerbach, et al.
The Journal of Sexual Medicine|October 30, 2014
Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasterideSidney Glina, Claus G Roehrborn, Adil Esen, et al.
Frontiers in Neurology|June 22, 2026
Evaluating the relationship between the 4-item migraine interictal burden scale and other patient-reported outcome measures: a <i>post hoc</i> analysis from a phase 3 migraine prevention studyChristian Lampl, Richard B Lipton, Sarah Lipsius, et al.
Pageof 12

Showing results (51-60 of 111) with videos related to

Sort By:
Pageof 12
Maturitas|June 13, 2008
Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinenceJules H Schagen van Leeuwen, Rainer R Lange, Aino Fianu Jonasson, et al.
Current Medical Research and Opinion|November 26, 2009
Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinenceLinda Cardozo, Rainer Lange, Simon Voss, et al.
Neurology and Therapy|April 10, 2025
Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records StudyOralee J Varnado, Michelle Vu, Gilwan Kim, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 11, 2012
Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian menOsamu Yokoyama, Masaki Yoshida, Sae Chul Kim, et al.
Urology|February 19, 2010
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunctionGregory A Broderick, Gerald B Brock, Claus G Roehrborn, et al.
Headache|April 22, 2026
Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3-Month results from the TRIUMPH studyShivang Joshi, Cristina Tassorelli, Manjit Matharu, et al.
European Urology|May 5, 2009
Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasiaHartmut Porst, Kevin T McVary, Francesco Montorsi, et al.
BJU International|September 8, 2009
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatmentClaus G Roehrborn, Jed C Kaminetsky, Stephen M Auerbach, et al.
The Journal of Sexual Medicine|October 30, 2014
Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasterideSidney Glina, Claus G Roehrborn, Adil Esen, et al.
Frontiers in Neurology|June 22, 2026
Evaluating the relationship between the 4-item migraine interictal burden scale and other patient-reported outcome measures: a <i>post hoc</i> analysis from a phase 3 migraine prevention studyChristian Lampl, Richard B Lipton, Sarah Lipsius, et al.
Pageof 12